“While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer’s disease, the extensive body of evidence supporting semaglutide continues to provide benefits for individuals with type 2 diabetes, obesity, and related comorbidities.”
Novo Nordisk announced that semaglutide, the active ingredient in Ozempic and Wegovy, failed to slow cognitive decline in two three-year trials of 3,808 adults with early Alzheimer’s. The drug did reduce inflammation markers by 30% but that didn’t translate to cognitive benefits. Researchers note that real-world data always suggested semaglutide might prevent dementia rather than treat it. The company has ended all semaglutide Alzheimer’s trials including tests of injectable versions.